Quoin Pharmaceuticals Ltd... (QNRX)
NASDAQ: QNRX
· Real-Time Price · USD
8.34
-0.08 (-0.95%)
At close: Jun 17, 2025, 10:55 AM
-0.95% (1D)
| Bid | 8.2 |
| Market Cap | 4.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.44M |
| EPS (ttm) | -34.62 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.6 |
| Analyst | Buy |
| Ask | 8.5 |
| Volume | 3,364 |
| Avg. Volume (20D) | 286,910 |
| Open | 8.52 |
| Previous Close | 8.42 |
| Day's Range | 8.20 - 8.53 |
| 52-Week Range | 5.01 - 54.95 |
| Beta | 1.78 |
About QNRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QNRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QNRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+0%
QNRX stock has given up its prior gain. Quoin Phar...
Unlock content with
Pro Subscription
3 weeks ago
+0%
Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.
4 months ago · accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...